Back to Journals » OncoTargets and Therapy » Volume 16

Berberine Reverses Doxorubicin Resistance by Inhibiting Autophagy Through the PTEN/Akt/mTOR Signaling Pathway in Breast Cancer [Retraction]

Authors Wang Y, Liu Y, Du X, Ma H, Yao J

Received 31 August 2023

Accepted for publication 31 August 2023

Published 5 September 2023 Volume 2023:16 Pages 725—726

DOI https://doi.org/10.2147/OTT.S438000



Wang Y, Liu Y, Du X, Ma H, Yao J. Onco Targets Ther. 2020;13:1909-1919.

We, the Editors and Publisher of OncoTargets and Therapy, have retracted the following article.

Since publication, concerns have been raised about the integrity of the data in the article. This includes the duplication of images from Figures 2 and 4. Specifically,

  • The western blot image for Figure 2B, MCF7/ADR, MDR1 appears to have been duplicated with the image for Figure 4C, MCF7/ADR, p62, which has been flipped.
  • The image for Figure 4B, MCF7/ADR, siPTEN, has been duplicated with the image for Figure 4D, MCF/ADR, BBR.
  • The western blot image for Figure 4C, MCF7/ADR, GAPDH, has been duplicated with the image for Figure 4E, MCF7/ADR, GAPDH.

When approached for an explanation, the authors did not respond to our queries, nor did they provide original data for their study. As the findings could not be verified the Editor and Publisher made the decision to retract the article and the authors were notified of this.

We have been informed in our decision-making by our editorial policies and COPE guidelines.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as ‘Retracted’.


This retraction relates to this paper


Creative Commons License © 2023 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.